Abstract
Objective:
Non-respiratory long-coronavirus disease 2019 (COVID-19) symptoms are mainly related to a long-lasting endothelial dysfunction and microcirculation impairment. We hypothesized that Sulodexide, a purified glycosaminoglycan mixture with a beneficial endothelial effect in arterial and venous peripheral diseases, may be effective in a subset of patients with long COVID-19.
Approach and Results:
We conducted a multicenter prospective quasi-experimental study. A total of 290 patients from the TUN-EndCOV study with long-COVID-19 symptoms and endothelial dysfunction were included. The endothelial function was clinically assessed using a post-occlusive reactive hyperemia protocol with finger thermal monitoring device. Endothelial quality index (EQI) was assessed at inclusion and at 21 days later. The study population was assigned to a sulodexide group (144 patients) or a no-medical treatment group (146 patients). Clinical characteristics were similar at inclusion in the two groups. Fatigue, shortness of breath, and chest pain were the most common symptoms, respectively, 54.5, 53.8, and 28.3%. At 21 days, the sulodexide group improved significantly better than the no-medical treatment group in chest pain (83.7 vs. 43.6%, p < 10−3), palpitations (85.2 vs. 52.9%, p = 0.009), and endothelial function [median delta-EQI 0.66 (0.6) vs. 0.18 (0.3); p < 10−3]. Endothelial function improvement was significantly correlated with chest pain and palpitations recovery (AUC, i.e., area under the curve = 0.66, CI [0.57– 0.75], p = 0.001 and AUC = 0.60, CI [0.51– 0.69], p = 0.03, respectively).
Conclusion:
Sulodexide significantly improves long-lasting post-COVID-19 endothelial dysfunction and alleviates chest pain and palpitations.
Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in China in December 2019 (1, 2). To date, more than 269 million people have been infected worldwide, and over 5 million people have died from the coronavirus disease 2019 (COVID-19) (3). The COVID-19 is a multisystem disease due to in part to the vascular endothelium injury (4, 5).
Beyond pulmonary injury, inflammation, and particularly cytokine storm, prothrombotic state and endothelial dysfunction are proved to be the main causes of detrimental outcome of patients with COVID-19 in the acute phase (6).
The new symptoms persisting 30 days after the onset of COVID-19, not explained by an alternative diagnosis, are frequently reported and are recognized by NICE guidelines as a “long-COVID-19 syndrome” (7). These symptoms are sometimes disabling and affect patient's quality of life and delay return to work (8). Besides the socioeconomic impact, the medical community is still not fixed on the possible causes, outcomes, and how to manage such patients. The non-understanding of patients by their doctors causes an increasingly perceived loss of confidence. Many recent reports raised the concern of long-lasting inflammation and endothelial dysfunction several months beyond the acute phase (9). In the cohort of 798 patients with long-COVID-19 from the TUN-EndCOV study, we found that about half (49.7%) of patients still have microcirculation impairment with a significant independent link between non-respiratory long-COVID-19 symptoms (chest pain, fatigue, and neurocognitive symptoms) and endothelial dysfunction in multivariate analysis (10). “ESC group for atherosclerosis and vascular biology” stated that it seems relevant to follow the endothelial function in convalescent patients for early detection and prevention of long-term cardiovascular complications (4). Endothelial cells dysfunction should be overlooked as a therapeutic target during acute and long COVID-19 (11, 12).
Long-COVID-19 management guidelines has been developed jointly by NICE, the Scottish Intercollegiate Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP) (7). These guidelines focused on ruling out organic diseases otherwise rehabilitation and psychological support are proposed. “What pathophysiological mechanisms underlie the most common presentations of post-COVID-19 syndrome?” is stated as a research recommendation (6, 9).
Sulodexide, a highly purified mixture of glycosaminoglycan that includes fast-moving heparin and dermatan sulfate, had beneficial effects on the fibrinolytic system, platelets, endothelial cells, and inflammation (13). Sulodexide used in the early stages of COVID-19 was associated with a limiting disease progression, a decreased need for oxygen support, and hospital care (14).
Sulodexide was not tested in the setting of long-COVID-19 syndrome. We hypothesized that it may be effective in the long-COVID-19 spectrum and particularly in the subset of symptoms linked to microcirculation impairment and endothelium dysfunction.
Materials and Methods
Study Design
This is a prospective multicenter quasi-experimental case–control study. The recruiting period extended from 20 January to 26 June 2021. The study protocol was recorded in the Pan African Clinical Trials Registries (PACTR) with trial ID PACTR202102867544936. The study had the local Ethics and Investigation Committee approval, being designated with approval number CPP SUD 0299/2020. All authors reviewed the manuscript for the accuracy and completeness of the data.
Patients
Patients were recruited by local health authorities relying on COVID-19 registry. The standard protocol of endothelial function study was previously detailed (10). After informed consent, all the eligible patients above 18 years old, with a recent diagnosis of COVID-19 infection in the past 1 to 6 months, confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal swabs or viral rapid test, were enrolled. The symptomatic patients with proven endothelial dysfunction [endothelial quality index (EQI) < 2], assessed by a post-occlusive reactive hyperemia (PORH) finger thermal monitoring (E4-diagnose, Polymath Company, Tunisia) (15), were assigned into two groups. The sulodexide group received sulodexide (Vessel, AlfaSigma, Italy) 250 LSU (lipasemic units, approximately equivalent to 25 mg) two times a day during 21 days. The control group adhered to the study protocol without any medical treatment (Figure 1).
Figure 1
The study flow chart.
Main exclusion criteria were the patients recovered from COVID-19 with a good endothelial function (EQI ≥ 2), patients under anticoagulation or having experienced venous thromboembolism in the past 6 months, patients with chronic use of steroid medication, patients with life expectancy <1 year, according to clinical judgment, patient with symptoms related to an organic cause [acute coronary syndrome (ACS), pericarditis, heart failure, pulmonary embolism, pulmonary disease, etc.], pregnancy and breastfeeding and foreseen inability to attend scheduled visits. Patients who did not attend the scheduled 21-day visit were excluded from the data analysis.
The long-COVID-19 symptoms were screened relying on long-COVID-19 NICE guidelines (7). Electrocardiogram (ECG), transthoracic echocardiogram (TTE), laboratory examinations, and endothelial function test were done in the same initial consultation (T0). Objective symptoms evaluation was performed according to clinical scores. Shortness of breath was defined by a New York Heart Association class of dyspnea ≥ 2 (17). Fatigue was evaluated according to the modified fatigue severity scale (18). We used the Mini-Mental State Examination (MMSE) to assess cognitive performances. Cognitive difficulties were defined by an MMSE score < 24 (19).
Ambulatory 24-h cardiac monitoring DMS 300-4L was performed only in patients with palpitations. At ECG analysis, elevated heart rate (HR) was defined by an HR > 100 beats at rest, and supraventricular premature beats were defined by ectopic beats with narrow QRS (QRS ≤ 120 ms) and abnormal P wave and ventricular premature beats by ectopic beats with large QRS (QRS > 120 ms) and not preceded by P waves (20). Holter analysis Software was Cardioscan Premier 12. At Holter monitoring, the isolated ventricular ectopics which were less than 10% and the isolated supraventricular episodes which were less than 10% were regarded as insignificant arrhythmias.
A second visit with another clinical assessment and a second endothelial function test were performed in all patients at 21 days after inclusion (T1).
Study End Points
Patient outcomes were assessed at 21 days after inclusion. Primary end points were: long-COVID-19 symptoms evolution from T0 to T1 and endothelial function outcome (delta EQI) defined as the difference between EQI at 21-day follow-up and EQI at inclusion. Delta EQI = EQI(T1)–EQI (T0).
Statistical Analysis
Statistical analyses were performed using SPSS, Chicago (Statistical Package for the Social Sciences) version 23.0. The complete database is maintained by the study team.
Since we included a large long-COVID-19 population, we calculated a mean EQI amelioration without medical intervention of 0.2 (0.6) in an initial sample of patients. We then anticipated a 60% power of EQI after medical intervention, and we calculated a sample size of 142 subjects in each group.
Categorical variables were expressed as frequencies and percentages. For quantitative variables, we checked the normality of the distribution by the Kolmogorov–Smirnov test and the Shapiro–Wilk test. An estimate of the means with their standard deviations (SDs) and of the median with interquartile range (IQR) was thus carried out.
The comparison between two categorical variables was carried out by the Pearson's chi-squared test test or the Fisher's exact test if the conditions were not verified.
The Student's t-test was used for the comparison of two means when the distribution was Gaussian and by the non-parametric U test of Mann–Whitney or Kruskal–Wallis when the distribution was not Gaussian.
The McNemar's test was used to determine if there were differences in paired data during the follow-up in the different study groups.
The area under the curve (AUC) using the receiver operating characteristic curves determined the correlation between the delta EQI and long-COVID-19 symptoms recovery.
Estimates of risk ratios were presented with 95% confidence intervals (CIs). The value of p < 0.05 was considered statistically significant.
Results
A total of 290 patients were included in this study at an average time of 70.81 (41.9) [28–180] days. They were assigned to a sulodexide group (144 patients) or a control group (146 patients). The demographics, clinical characteristics, and the number of chronic medications used by the patients were similar in the two study groups (Table 1). The median age was 54.15 (12.8) years. Females accounted for 54.1% of the participants (157 of 290). Hypertension was the most common chronic health condition, reported in 36.9% (107 of 290) and followed by diabetes 27.9% (81 of 290). The severity of COVID-19 infection, the extent of lesions at initial thoracic CT scan, and the average time between COVID-19 infection and inclusion were similar in the two groups (Table 1). The ECG analysis revealed an elevated HR at rest and premature supra ventricular and ventricular beats in 37 (12.8%), 13 (4.4%), and 14 (4.8%) of patients, respectively. Only 61 (21%) patients had ambulatory 24-h cardiac monitor. Holter monitoring analysis showed that among these patients, 19 (31.1%), 9 (14.8%), and 4 (6.6%) had sinus tachycardia, significantly isolated supra ventricular episodes, and ventricular ectopic beats, respectively. The rates of elevated HR at rest and premature beats were similar in the two groups (Table 1). The median troponin was 1.8 (2.3) ng/L. All patients had normal range troponin. The left ventricle ejection fraction (LVEF) in echocardiography was normal and similar in the two groups and there was no pericardial effusion (Table 1). Among the long-COVID-19 symptoms, fatigue was the most common symptom, reported in 54.5% (158 of 290), followed by shortness of breath reported in 53.8% (156 of 290) and chest pain 28.3% (82 of 290) (Table 1). The long-COVID-19 symptoms were similar in the two study groups (Table 1). Long-COVID-19 symptoms improved significantly at the 21-day follow-up in the 2 study groups (Table 2). At 21 days, the sulodexide group presented significantly less chest pain (83.7 vs. 43.6%, p < 10−3) and palpitations (85.2 vs. 52.9%, p = 0.009) than controls (Table 2). There was a trend of a significant decrease in fatigue (82.5 vs. 70.5%, p = 0.07) and neurocognitive disorders (78.9 vs. 53.8%, p = 0.08). The sulodexide group presented also a significant endothelial function amelioration compared to control group [median delta-EQI 0.66 (0.6) vs. 0.18 (0.3); p < 10−3] (Figure 2). Endothelial function improvement was significantly correlated with chest pain and palpitations recovery (AUC = 0.66, CI [0.57–0.75], p = 0.001 and AUC = 0.60, CI [0.51–0.69], p = 0.03, respectively) (Table 3, Figure 3).
Table 1
| Total population (N = 290) | Sulodexide Group (N = 144) | No medical treatment Group (N = 146) | p-value | |
|---|---|---|---|---|
| Demographics and Clinical characteristics | ||||
| Age (years) (mean, SD) | 54.15 (12.8) | 55.36 (12.9) | 52.97 (12.6) | 0.11 |
| BMI (kg/m2) (median, IQR) | 28.6 (4.5) | 28.7 (2.4) | 28.4 (2.8) | 0.77* |
| Females (n, %) | 157 (54.1) | 73 (50.7) | 84 (57.5) | 0.24 |
| Diabetes (n, %) | 81 (27.9) | 44 (30.6) | 37 (25.3) | 0.32 |
| Hypertension (n, %) | 107 (36.9) | 58 (40.3) | 49 (33.6) | 0.23 |
| Dyslipidemia (n, %) | 45 (15.5) | 25 (17.4) | 20 (13.7) | 0.38 |
| Smoking (n, %) | 20 (6.9) | 7 (4.9) | 13 (8.9) | 0.17 |
| Heart failure (n, %) | 5 (1.7) | 3 (2.1) | 2 (1.4) | 0.64 |
| Coronary heart disease (n, %) | 17 (5.9) | 12 (8.3) | 5 (3.4) | 0.07 |
| Pulmonary disease (n, %) | 14 (4.8) | 6 (4.2) | 8 (5.5) | 0.60 |
| Chronic medications before trial | ||||
| Aspirin (n, %) | 21 (7.2) | 13 (9.0) | 8 (5.5) | 0.24 |
| RAAS Blockers (n, %) | 86 (29.7) | 46 (31.9) | 40 (27.4) | 0.39 |
| Bblockers (n, %) | 45 (15.5) | 28 (19.4) | 17 (11.6) | 0.06 |
| Statins (n, %) | 60 (20.7) | 35 (24.3) | 25 (17.1) | 0.13 |
| Severity of COVID 19 infection | ||||
| Moderate or severe symptoms (need of oxygen) (n, %) | 107 (36.9) | 56 (38.9) | 51 (34.9) | 0.48 |
| Extend of lesions at thoracic CT scan | ||||
| ≥50 % (n, %) | 29 (10) | 13 (44.8) | 16 (55.2) | 0.58 |
| Delay between COVID-19 infection and inclusion (days) | 70.81 (41.9) | 72.87 (41.1) | 68.77 (42.7) | 0.40 |
| Electrocardiogram | ||||
| Heart rate (mean, SD) | 77.45 (11.3) | 78.93 (12.4) | 76.31 (10.3) | 0.15 |
| Heart rate at rest > 100 (n, %) | 37 (12.8) | 18 (12.5) | 19 (13.0) | 0.89 |
| Premature supra ventricular complexes (n, %) | 13 (4.4) | 6 (4.1) | 7 (4.8) | 0.84 |
| Premature Ventricular complexes (n, %) | 14 (4.8) | 7 (4.9) | 7 (4.8) | 0.97 |
| Troponin (ng/L) (median, IQR) | 1.8 (2.3) | 1.6 (3.3) | 1.85 (1.7) | 0.69* |
| Ambulatory cardiac monitor (n, %) | 61 (16) | 27 (18.8) | 34 (23.3) | 0.34 |
| Echocardiographic parameters | ||||
| LVEF (%) (median, IQR) | 61 (4) | 61 (2.5) | 61.5 (4) | 0.64* |
| Pericardial effusion (n, %) | 0 | 0 | 0 | - |
| Long covid symptoms | ||||
| Fatigue (n, %) | 158 (54.5) | 80 (55.6) | 78 (53.4) | 0.71 |
| Chest pain (n, %) | 82 (28.3) | 43 (29.9) | 39 (26.7) | 0.55 |
| Palpitations (n, %) | 61 (16) | 27 (18.8) | 34 (23.3) | 0.34 |
| Shortness of breath (n, %) | 156 (53.8) | 71 (49.3) | 85 (58.2) | 0.12 |
| Cough (n, %) | 45 (15.5) | 23 (16.0) | 22 (15.1) | 0.83 |
| Headaches (n, %) | 76 (26.2) | 31 (21.5) | 45 (30.8) | 0.07 |
| Gastro-intestinal syndrome (n, %) | 25 (8.6) | 8 (5.6) | 17 (11.6) | 0.06 |
| Anosmia (n, %) | 11 (3.8) | 3 (2.1) | 8 (5.5) | 0.13 |
| Neuro-cognitive difficulties (n, %) | 45 (15.5) | 19 (13.2) | 26 (17.8) | 0.27 |
Baseline characteristics of the study population.
BMI, body mass index; EQI, endothelium quality index; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; RAAS, renin angiotensin aldosterone system.
Mann–Whitney U test.
Table 2
| Sulodexide group (N=144) | No medical treatment group (N=146) | p-value † % recovery | |||||||
|---|---|---|---|---|---|---|---|---|---|
| T0 | T1 | p-value* | % Recovery | T0 | T1 | p-value* | % Recovery | ||
| Chest pain (n, %) | 43 (29.9) | 7 (4.9) | <0.001 | 36/43 (83.7) | 39 (26.7) | 19 (13) | <0.001 | 20/39 (43.6) | <10−3 |
| Palpitations (n, %) | 27 (18.8) | 4 (2.7) | <0.001 | 23/27 (85.2) | 34 (23.3) | 16 (10.9) | <0.001 | 18/34 (52.9) | 0.009 |
| Fatigue (n, %) | 80 (55.6) | 14 (9.7) | <0.001 | 66/80 (82.5) | 78 (53.4) | 23 (15.8) | <0.001 | 55/78 (70.5) | 0.07 |
| Shortness of breath (n, %) | 71 (49.3) | 20 (13.9) | <0.001 | 51/71 (71.8) | 85 (58.2) | 32 (21.9) | <0.001 | 53/85 (62.4) | 0.21 |
| Cough (n, %) | 23 (16.0) | 4 (2.8) | <0.001 | 19/23 (82.6) | 22 (15.1) | 8 (5.5) | <0.001 | 14/22 (63.6) | 0.15 |
| Headaches (n, %) | 31 (21.5) | 7 (4.9) | <0.001 | 24/30 (80) | 45 (30.8) | 16 (11) | <0.001 | 29/45 (64.4) | 0.14 |
| Gastro-intestinal syndrome (n, %) | 8 (5.6) | 1 (0.7) | 0.01 | 7/8 (87.5) | 17 (11.6) | 5 (3.4) | <0.001 | 12/17 (70.6) | 0.35 |
| Anosmia (n, %) | 3 (2.1) | 1 (0.7) | 0.5 | 2/3 (66.7) | 8 (5.5) | 2 (1.4) | 0.03 | 6/8 (75) | 0.78 |
| Neuro-cognitive difficulties (n, %) | 19 (13.2) | 4 (2.8) | <0.001 | 15/19 (78.9) | 26 (17.8) | 12 (8.2) | <0.001 | 14/26 (53.8) | 0.08 |
Evolution of the long-COVID-19 symptoms in the study groups.
ACS, acute coronary syndrome; T0, Symptoms' assessment at inclusion; T1, symptoms' assessment at 21-day follow-up.
McNemar's test;
chi-squared test.
Bold values refer to significant p-value.
Figure 2
Evolution of the endothelium quality index (delta EQI) at 21-days follow-up in the 2 study groups.
Table 3
| AUC | CI | p-value | |
|---|---|---|---|
| Chest pain | 0.66 | [0.57–0.75] | 0.001 |
| Palpitations | 0.60 | [0.51–0.69] | 0.03 |
| Fatigue | 0.52 | [0.45–0.59] | 0.47 |
| Shortness of breath (dyspnea) | 0.49 | [0.42–0.56] | 0.83 |
| Cough | 0.54 | [0.44–0.55] | 0.35 |
| Headaches | 0.57 | [0.50–0.65] | 0.07 |
| Gastro-intestinal syndrome | 0.51 | [0.38–0.64] | 0.82 |
| Anosmia | 0.39 | [0.20–0.58] | 0.30 |
| Neuro-cognitive difficulties | 0.53 | [0.43–0.63] | 0.55 |
Correlation between endothelial function improvement and long-COVID-19 symptoms recovery.
AUC, Area under the curve; CI, confidence interval.
Figure 3
ROC analysis for endothelial function amelioration and (A) chest pain recovery, (B) palpitations recovery.
Discussion
Our findings provide evidence that sulodexide significantly improves long-lasting post-COVID-19 endothelial dysfunction and alleviates chest pain and palpitations.
In our study, we found that fatigue, shortness of breath, and chest pain were the most reported post-COVID-19 sequalae. Long-COVID-19 syndrome was characterized by a combination of non-specific symptoms. Cardiovascular (CV) symptoms especially chest pain and palpitations were frequently reported (16, 21–23).
The underlying pathophysiology of CV symptoms is not yet well defined. Several explanations have been proposed, for example, a microvascular and endothelial dysfunction (24–26), vascular pericyte involvement (27), a systemic and myocardial inflammation (28, 29), an immune dysregulation, and a nervous system autonomic instability (30).
To date, only limited series of in-vitro trials were available and there were no published in-vivo trials in the long-COVID 19 setting.
In a previous publication of TUN-EndCOV, we found that about half (49.7%) of patients still have microcirculation impairment monitored by a non-invasive PORH finger thermal device. Endothelial dysfunction (EQI < 2) was significantly related to non-respiratory long-COVID 19 symptoms (chest pain, fatigue and neurocognitive symptoms) in multivariate analysis (OR = 1.522 (1.072–2.160), p = 0.019) (10). These findings suggest that persistent microvascular and endothelial dysfunction could explain a subset of long-COVID-19 symptoms. Another study investigated in-vivo vascular endothelial function with a non-invasive peripheral arterial tonometry (Endopat, Itamar). In 3 matched series, flow-mediated dilation of peripheral arteries was substantially lower in patients with post-COVID-19 when compared to acute infection and controls (9).
These findings support the evidence of increased rates of vascular complications in patients with post-COVID-19 compared to general population and the necessity of effective treatment to avoid such complications (31). The increasing number of symptomatic patients with long COVID-19 looking for an effective solution is nowadays a real health public problem. NICE guidelines focused on ruling out organic diseases otherwise rehabilitation and psychological support are proposed (7). Betablockers and ivabradine were proposed in patients with post-orthostatic tachycardia syndrome (POTS) (32). Otherwise, statins, oral anticoagulants, and antidepressors were suggested and widely used in daily practice without sufficient evidence (32).
In a review about the pathogenesis of COVID-19 through the lens of an undersulfated and degraded epithelial and endothelial glycocalyx, the prevention and treatment protocols proposed were to preserve and repair epithelial and endothelial glycocalyx integrity (33). This objective seems to be relevant to the patients with post-COVID-19 with persistent glycocalyx damage and endothelial dysfunction (34, 35).
Since endothelial dysfunction seems to be a serious driving cause of non-respiratory long-COVID-19 symptoms, we hypothesized that targeting microvascular impairment could be an effective solution. In this quasi-experimental TUN-EndCOV study, we have selected sulodexide (Vessel, AlfaSigma, Italy) 250 LSU two times a day during 21 days for symptomatic patients with proven endothelial dysfunction (EQI < 2). A clinical assessment and endothelial function test were performed in all patients at inclusion and at 21 days later.
Sulodexide, an orally administered highly purified mixture of glycosaminoglycan that includes fast-moving heparin and dermatan sulfate, had beneficial effects on the fibrinolytic system, platelets, endothelial cells, and inflammation (13). Sulodexide is known by its pleotropic action and protective effect on the endothelium (36, 37). It presents antithrombotic properties through reduction of fibrinogen (38, 39) and plasminogen activator inhibitor-1 (PAI-1) (38, 40) and is thought to have anti-inflammatory properties (39–42). Across different cardiovascular indications, the use of sulodexide was associated with reduced risk of venous thromboembolism, myocardial infarction, cardiovascular mortality, and all-cause mortality (43, 44). Despite the potential interest, limited data exist about the safety and efficacy of sulodexide in patients with COVID-19 (45, 46). A randomized study supports the effectiveness of sulodexide in mitigating the severe clinical progression rate of COVID-19, compared to the prevalent standard of care, when used in the early symptomatic stages of the disease by decreasing the need for hospital admission, oxygen requirements, and the serum levels of inflammatory and prothrombotic markers (14). These findings, especially lower inflammatory and prothrombotic markers, could explain faster endothelium restoration after a COVID-19 infection.
Our results support evidence that sulodexide significantly improves long-lasting post-COVID-19 endothelial dysfunction and alleviates related chest pain (83.7%, p < 10−3) and palpitations (85.2%, p = 0.009). There was also a trend of a significant decrease in fatigue (82.5%, p = 0.07) and neurocognitive disorders (78.9%, p = 0.08).
TUN-EndCOV trial is not only the largest in-vivo trial that has proved that non-respiratory long-COVID-19 symptoms are related to endothelial dysfunction but is also the first to prove that targeting these symptoms by sulodexide could be an effective solution for more than 80% of patients within a short-time medication of 3 weeks. Non-respiratory symptoms recovery was in parallel with endothelial function restoration. TUN-EndCOV is a real-life study, in which patients with cofactors of endothelial dysfunction (diabetes, hypertension, age, obesity, etc.) were not under represented as it could be in a randomized study. Our findings support the emphasized patients' hope in regaining their wellbeing and accelerating their return to work. The synergic activity of sulodexide's components and its pleiotropic effects may be essential to reach such results.
Limitations and Perspectives
The main limitations of the study:
- This was a quasi-experimental study with a control group. The need of placebo-randomized study is warranted to confirm such results.
- Further studies with larger population are needed to confirm the significant recovery of the other “non-respiratory” symptoms such as neurocognitive difficulties and fatigue.
- Limited follow-up of 3 weeks. Long-term follow-up is needed for major events (mortality, thromboembolic complications, stroke, myocardial injury, etc.) analysis.
- Only sulodexide with one-dose regimen has been tested. Further studies with other protocols and drugs targeting endothelial dysfunction must be conducted.
- Only symptomatic patients with proven endothelial dysfunction were included which raises the concern of need and availability of such tests in clinical practice.
Conclusion
Long-lasting microcirculation and endothelial dysfunction have been proved in-vitro and in-vivo studies in convalescent patients with COVID-19. Non-respiratory symptoms may be related to microcirculation impairment. Our results support that targeting this cause with sulodexide accelerates patients' recovery in parallel with vascular endothelium restoration. Other clinical trials are warranted.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the study had the local Ethics and Investigation Committee approval, being designated with approval number CPP SUD 0299/2020. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions
LA, SA, SC, HI, and JJ conceived and designed the study, had full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis. SC, SA, JJ, and LA drafted the paper and performed the analysis. ST, SK, AG, ZM, and YT contributed to data collection and interpretation. All authors critically revised the manuscript for relevant intellectual content and gave final approval for the version to be published. All authors agree to be accountable for all aspects of the work and will answer any questions related to the accuracy or integrity of the work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
HuangCWangYLiXRenLZhaoJHuYet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
2.
ZhuNZhangDWangWLiXYangBSongJet al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. 10.1056/NEJMoa2001017
3.
Johns Hopkins Coronavirus Resource Center. Available online at: https://coronavirus.jhu.edu/ (accessed August 2021).
4.
EvansPCRaingerGEMasonJCGuzikTJOstoEStamatakiZet al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. (2020) 116:2177–84. 10.1093/cvr/cvaa230
5.
LevyJHIbaTGardinerEE. Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol. (2021) 41:1774–6. 10.1161/ATVBAHA.121.316101
6.
NägeleMPHaubnerBTannerFCRuschitzkaFFlammerAJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. (2020) 314:58–62. 10.1016/j.atherosclerosis.2020.10.014
7.
ShahWHillmanTPlayfordEDHishmehL. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ.(2021) 372:n136. 10.1136/bmj.n136
8.
Lopez–LeonSWegman–OstroskyTPerelmanCSepulvedaRRebolledoPCuapioAet al. More than 50 long–term effects of COVID-19: a systematic review and meta–analysis. Res Sq. (2021) 11:1–2. 10.1038/s41598-021-95565-8
9.
Mejia–RenteriaHTraviesoASagirAMartínez–GómezECarrascosa-GranadaAToyaTet al. In–vivo evidence of systemic endothelial vascular dysfunction in COVID-19. Int J Cardiol. (2021) 345:153–5. 10.1016/j.ijcard.2021.10.140
10.
CharfeddineSIbn Hadj AmorHJdidiJTorjmenSKraiemSHammamiRet al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights From TUN-EndCOV study. Front Cardiovasc Med. (2021) 8:1702. 10.3389/fcvm.2021.745758
11.
CaoR–NTangLXiaZ–YXiaR. Endothelial glycocalyx as a potential theriapeutic target in organ injuries. Chin Med J. (2019) 132:963–75.
12.
KadoshBSGarshickMSGaztanagaJMooreKJNewmanJDPillingerMet al. COVID-19 and the heart and vasculature: novel approaches to reduce virus–induced inflammation in patients with cardiovascular disease. Arterioscler Thromb Vasc Biol. (2020) 40:2045–53. 10.1161/ATVBAHA.120.314513
13.
HoppensteadtDAFareedJ. Pharmacological profile of sulodexide. Int Angiol J Int Union Angiol. (2014) 33:229–35.
14.
Gonzalez OchoaAJRaffettoJHernandez IbarraAGZavalaNGutierrezOVargasAet al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. (2021) 121:944–54. 10.1055/a-1414-5216
15.
Polymath-Diagnose User Manual.pdf.
16.
GreenhalghTKnightM. A'Court C, Buxton M, Husain L. Management of post–acute COVID-19 in primary care. BMJ. (2020) 370:m3026. 10.1136/bmj.m3026
17.
YapJLimFYGaoFTeoLLLamCSPYeoKK. Correlation of the New York heart association classification and the 6–minute walk distance: a systematic review. Clin Cardiol. (2015) 38:621–8.
18.
KosDKerckhofsECarreaIVerzaRRamosMJansaJ. Evaluation of the Modified Fatigue Impact Scale in four different European countries. Mult Scler Houndmills Basingstoke Engl. (2005) 11:76–80. 10.1191/1352458505ms1117oa
19.
PangmanVCSloanJGuseL. An examination of psychometric properties of the mini–mental state examination and the standardized mini–mental state examination: implications for clinical practice. Appl Nurs Res ANR. (2000) 13:209–13. 10.1053/apnr.2000.9231
20.
CalkinsH. The 2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia. Eur Heart J. (2019) 40:3812–3. 10.1093/eurheartj/ehz837
21.
NabaviN. Long covid: How to define it and how to manage it. BMJ.(2020) 370:m3489. 10.1136/bmj.m3489
22.
NalbandianASehgalKGuptaAMadhavanMVMcGroderCStevensJSet al. Post–acute COVID-19 syndrome. Nat Med. (2021) 27:601–15. 10.1038/s41591-021-01283-z
23.
DixitNMChurchillANsairAHsuJJ. Post–Acute COVID-19 Syndrome and the cardiovascular system: What is known?Am Heart J Plus Cardiol Res Pract. (2021) 5:100025. 10.1016/j.ahjo.2021.100025
24.
AkhmerovAMarbánE. COVID-19 and the Heart. Circ Res. (2020) 126:1443–55. 10.1161/CIRCRESAHA.120.317055
25.
VargaZFlammerAJSteigerPHabereckerMAndermattRZinkernagelASet al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417–8. 10.1016/S0140-6736(20)30937-5
26.
TajbakhshAGheibi HayatSMTaghizadehHAkbariAInabadiMSavardashtakiAet al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. (2021) 19:345–57.
27.
AvolioECarrabbaMMilliganRKavanagh WilliamsonMBeltramiAPGuptaKet al. The SARS–CoV−2 Spike protein disrupts human cardiac pericytes function through CD147 receptor–mediated signalling: a potential non–infective mechanism of COVID-19 microvascular disease. Clin Sci Lond Engl. (2021) 135:2667–89. 10.1042/CS20210735
28.
FoxSELiGAkmatbekovAHarbertJLLameiraFSBrownJQet al. Unexpected Features of Cardiac Pathology in COVID-19 Infection. Circulation. (2020) 142:1123–5. 10.1161/CIRCULATIONAHA.120.049465
29.
CamazónNVTeisAMembriveMJMLlibreCBayés–GenísAMateuL. Long COVID-19 and microvascular disease–related angina. Rev Esp Cardiol. (2021) 142:1123–1125.
30.
DaniMDirksenATaraborrelliPTorocastroMPanagopoulosDSuttonRet al. Autonomic dysfunction in ≪ long COVID ≫: rationale, physiology and management strategies. Clin Med Lond Engl. (2021) 21:e63–7. 10.7861/clinmed.2020-0896
31.
AyoubkhaniDKhuntiKNafilyanVMaddoxTHumberstoneBDiamondIet al. Post–covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ.(2021) 372:n693. 10.1136/bmj.n693
32.
YongSJLiuS. Proposed subtypes of post-COVID-19 syndrome (or long–COVID) and their respective potential therapies. Rev Med Virol. (2021) e2315. 10.1002/rmv.2315 [Online ahead of print].
33.
du PreezHNAldousCHaydenMRKrugerHGLinJ. Pathogenesis of COVID-19 described through the lens of an undersulfated and degraded epithelial and endothelial glycocalyx. FASEB J Off Publ Fed Am Soc Exp Biol. (2022) 36:e22052. 10.1096/fj.202101100RR
34.
VollenbergRTepasseP–ROchsKFloerMStraussMRennebaumFet al. Indications of persistent glycocalyx damage in convalescent COVID-19 patients: a prospective multicenter study and hypothesis. Viruses. (2021) 13.
35.
FogartyHTownsendLMorrinHAhmadAComerfordCKarampiniEet al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost JTH. (2021) 19:2546–53. 10.1111/jth.15490
36.
ShenDChenRZhangLRaoZRuanYLiLet al. Sulodexide attenuates endoplasmic reticulum stress induced by myocardial ischaemia/reperfusion by activating the PI3K/Akt pathway. J Cell Mol Med. (2019) 23:5063–75. 10.1111/jcmm.14367
37.
DognéSFlamionBCaronN. Endothelial Glycocalyx as a Shield Against Diabetic Vascular Complications: Involvement of Hyaluronan and Hyaluronidases. Arterioscler Thromb Vasc Biol. (2018) 38:1427–39. 10.1161/ATVBAHA.118.310839
38.
Lasierra–CirujedaJCoronelPAzaMGimenoM. Use of sulodexide in patients with peripheral vascular disease. J Blood Med. (2010) 1:105–15. 10.2147/JBM.S10558
39.
LauverDALucchesiBR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. (2006) 24:214–26. 10.1111/j.1527-3466.2006.00214.x
40.
MauroMPalmieriGCPalazziniEBarbantiMCalanni RindinaFMilaniMR. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo–controlled study with an enteric–coated formulation. Curr Med Res Opin. (1993) 13:87–95. 10.1185/03007999309111537
41.
FemianoFGombosFScullyC. Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide. Int J Dermatol. (2003) 42:394–7. 10.1046/j.1365-4362.2003.01853.x
42.
BilinskaMWolszakiewiczJDudaMJanasJBeresewiczAPiotrowiczR. Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study. Med Sci Monit Int Med J Exp Clin Res déc. (2009) 15:CR618–623.
43.
BikdeliBChatterjeeSKirtaneAJParikhSAAndreozziGMDesaiNRet al. Sulodexide versus control and the risk of thrombotic and hemorrhagic events: meta–analysis of randomized trials. Semin Thromb Hemost. (2020) 46:908–18. 10.1055/s-0040-1716874
44.
JiangQ–JBaiJJinJShiJQuL. Sulodexide for secondary prevention of recurrent venous thromboembolism: a systematic review and meta–analysis. Front Pharmacol. (2018) 9:876. 10.3389/fphar.2018.00876
45.
BikdeliBMadhavanMVGuptaAJimenezDBurtonJRDer NigoghossianCet al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. (2020) 120:1004–24. 10.1055/s-0040-1713152
46.
MagnaniHN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. (2021) 27:1076029620977702. 10.1177/1076029620977702
Summary
Keywords
COVID-19, sulodexide, long COVID-19 syndrome, endothelial dysfunction, microcirculation
Citation
Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A, Makni A, Kallel N, Moussa N, Boudaya M, Touil I, Ghrab A, Elghoul J, Meddeb Z, Thabet Y, Ben Salem K, Addad F, Bouslama K, Milouchi S, Hammami R, Abdessalem S and Abid L (2022) Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study. Front. Cardiovasc. Med. 9:866113. doi: 10.3389/fcvm.2022.866113
Received
30 January 2022
Accepted
23 March 2022
Published
12 May 2022
Volume
9 - 2022
Edited by
Margreet R. De Vries, Leiden University Medical Center, Netherlands
Reviewed by
Kai Chen, University of Connecticut, United States; Jawed Fareed, Loyola University Medical Center, United States
Updates
Copyright
© 2022 Charfeddine, Ibnhadjamor, Jdidi, Torjmen, Kraiem, Bahloul, Makni, Kallel, Moussa, Boudaya, Touil, Ghrab, Elghoul, Meddeb, Thabet, Ben Salem, Addad, Bouslama, Milouchi, Hammami, Abdessalem and Abid.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Salma Charfeddine Selma_charfeddine@yahoo.fr
This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.